Andrea Lobo, PhD,  science writer—

Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.

Articles by Andrea Lobo

FDA grants orphan drug status to BLR-200 for scleroderma

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to BLR-200, a medication that BLR Bio — a company stemming from the Helix 51 biomedical incubator at Rosalind Franklin University — is developing for scleroderma. According to Ronald Kaplan, PhD, the…

SSc associated with worse outcomes in hospitalized COVID-19 patients

Hospitalized patients with COVID-19 are more likely to have worse outcomes if they also have systemic sclerosis (SSc), a study finds. This risk was assessed by a composite score that combined several clinical measures, including in-hospital mortality, invasive mechanical ventilation to help with breathing, use of medications to raise…

Malnutrition may be common in people with systemic scleroderma

More than half of the people with systemic sclerosis (SSc) in a study were malnourished under recent French guidelines, one-quarter had severe malnutrition, and being malnourished associated with cardiac involvement, a study in that country reported. Gastrointestinal (GI) tract involvement, not surprisingly, also was evident in a majority of…